EichorEICHOR
Study identifier: NCT07681323 Synced from ClinicalTrials.gov · August 05, 2026
● Recruiting

Timing of ctDNA Testing in Advanced Breast Cancer

Condition: Advanced Breast Cancer  ·  Sponsor: Geneplus-Beijing Co. Ltd.

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Fei Ma, MD  ·  +8615010127581  ·  drmafei@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Institute and Hospital, Chinese Academy of Medical SciencesBeijing, ChinaRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07681323